Examples: breast cancer, NCT03147287, pd-l1

Top 100 results for: "brain cancer"

Not Enrolling

A pilot surgical trial to evaluate early immunologic pharmacodynamic parameters for the PD-1 checkpoint inhibitor, pembrolizumab (MK-3475), in patients with surgically accessible recurrent/progressive glioblastoma

Trial Description: This research study is studying an immunotherapy as a possible treatment for Glioblastoma

  • Conditions: brain cancer
  • Phase: I
  • Trial ID: NCT02852655
  • Protocol ID: 16-225

Enrolling

Phase 0/I study of AMG 232 concentrations in brain tissue in patients with recurrent glioblastoma and of AMG 232 in combination with radiation in patients with newly diagnosed glioblastoma and unmethylated MGMT promoters

Trial Description: This phase I trial studies the side effects and best dose of navtemadlin in treating patients with glioblastoma (brain cancer) that is newly diagnosed or has come back (recurrent). Navtemadlin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

  • Conditions: glioblastoma, gliosarcoma, mgmt-unmethylated glioblastoma, recurrent glioblastoma
  • Phase: I
  • Trial ID: NCT03107780
  • Protocol ID: 17-453

Enrolling

A Phase I Study of the Treatment of Recurrent Malignant Glioma with rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and immunomodulation with Cyclophosphamide (Dana Farber Cancer Institute/ Brigham and Women s Hospital)

Trial Description: This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor.

  • Conditions: anaplastic oligodendroglioma of brain (diagnosis), astrocytoma, brain cancer, brain tumor, ependymoma, ganglioglioma, glioblastoma, glioblastoma multiforme, glioma, malignant astrocytoma, malignant glioma of brain, mixed oligo-astrocytoma, oligodendroglioma, pylocytic/pylomyxoid astrocytoma
  • Phase: I
  • Trial ID: NCT03152318
  • Protocol ID: 16-557

Enrolling

A double-blind, phase II randomized study of brain-directed stereotactic radiation with or without AGuIX gadolinium-based nanoparticles in the management of brain metastases at higher risk of local recurrence with radiation alone

Trial Description: The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.

  • Conditions: aguix, brain cancer, brain metastases, brain tumor, breast cancer, colorectal cancer, cystic, gastrointestinal cancer, her2-positive breast cancer, lung cancer, melanoma, nanoparticle, srs, srt, stereotactic radiation, whole brain radiation
  • Phase: II
  • Trial ID: NCT04899908
  • Protocol ID: 20-240

Enrolling

Screening MRI of the brain in patients with metastatic breast cancer managed with first through fourth line chemotherapy or inflammatory breast cancer managed with definitive intent: A prospective study

Trial Description: This research study is studying the usefulness of magnetic resonance imaging (MRI) to screen for brain metastases (spread of the breast cancer to the brain).

  • Conditions: breast cancer, her2-positive breast cancer, hormone receptor positive malignant neoplasm of breast, inflammatory breast cancer, metastatic breast cancer, triple negative breast cancer
  • Phase: II
  • Trial ID: NCT04030507
  • Protocol ID: 19-066

Enrolling

A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Trial Description: This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or does not respond to therapy (progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells grow without stopping. Vinblastine blocks cell growth by stopping cell division and may kill cancer cells. Giving selumetinib in combination with vinblastine may work better than selumetinib alone in treating recurrent or progressive low-grade glioma.

  • Conditions: recurrent low grade astrocytoma, recurrent who grade 2 glioma, refractory low grade astrocytoma, refractory low grade glioma, refractory who grade 1 glioma
  • Phase: III
  • Trial ID: NCT04576117
  • Protocol ID: 22-106

Enrolling

Phase II Trial of GDC-0084 in combination with Trastuzumab for Patients with HER2-Positive Breast Cancer Brain Metastases

Trial Description: This research study is studying a drug called GDC-0084 as a possible treatment for HER2-Positive Breast Cancer. The drugs involved in this study are: - GDC-0084 - Trastuzumab (Herceptin®)

  • Conditions: breast cancer
  • Phase: II
  • Trial ID: NCT03765983
  • Protocol ID: 18-516

Not Enrolling

A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis

Trial Description: This research study is studying the combination of a drug called atezolizumab and a radiation procedure called stereotactic radiosurgery (SRS) as a possible treatment for triple-negative breast cancer that has spread to the brain. The interventions involved in this study are: - Atezolizumab - Stereotactic radiosurgery (SRS)

  • Conditions: breast cancer
  • Phase: II
  • Trial ID: NCT03483012
  • Protocol ID: 17-519

Enrolling

GCC1949: Phase 2 trial of indoximod with chemotherapy and radiation for children with progressive brain tumors or newly diagnosed DIPG

by adding indoximod immunotherapy during chemotherapy and/or radiation is a potent approach for breaking immune tolerance to pediatric tumors that will improve outcomes, relative to standard therapy alone. This is an NCI-funded (R01 CA229646, MPI: Johnson and Munn) open-label phase 2 trial using indoximod-based combination chemo-radio-immunotherapy for treatment of patients age 3 to 21 years who have progressive brain cancer (glioblastoma, medulloblastoma, or ependymoma), or newly-diagnosed diffuse intrinsic pontine glioma (DIPG). Statistical analysis will stratify patients based on whether

  • Conditions: diffuse intrinsic pontine glioma, ependymoma, glioblastoma, medulloblastoma
  • Phase: II
  • Trial ID: NCT04049669
  • Protocol ID: 22-261

Enrolling

Whole brain radiation versus stereotactic radiation in patients with 5-20 brain metastases: A phase III, randomized clinical trial

Trial Description: This research study is studying two different types of radiation as treatment for brain metastases (tumors in the brain that spread from a cancer that originated elsewhere in the body)

  • Conditions: brain metastases
  • Phase: III
  • Trial ID: NCT03075072
  • Protocol ID: 16-305

Enrolling

A PHASE II TRIAL OF SACITUZUMAB GOVITECAN (IMMU-132) (NSC #820016) FOR PATIENTS WITH HER2-NEGATIVE BREAST CANCER AND BRAIN METASTASES

Trial Description: This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan may shrink the cancer in the brain and/or extend the time until the cancer gets worse.

  • Conditions: anatomic stage iv breast cancer ajcc v8, invasive breast carcinoma, metastatic her2 negative breast carcinoma, metastatic malignant neoplasm in the brain, prognostic stage iv breast cancer ajcc v8
  • Phase: II
  • Trial ID: NCT04647916
  • Protocol ID: 21-531

Not Enrolling

Preventative Skin Care for Children Undergoing Targeted Tumor Therapy for CNS and PNS Tumors

Trial Description: This research study is examining a preventive skin care regimen for children diagnosed with a brain tumor and receiving anti-cancer therapy with a MEK, Pan-RAF, or BRAF inhibitor.

  • Conditions: cns tumor childhood, pediatric cancer, skin inflammation
  • Phase: II
  • Trial ID: NCT04479514
  • Protocol ID: 19-579

Not Enrolling

FEASIBILITY OF THE LUM IMAGING SYSTEM FOR IN VIVO AND EX VIVO DETECTION OF CANCER IN SUBJECTS WITH LOW GRADE GLIOMAS, GLIOBLASTOMAS AND CANCER METASTASES TO THE BRAIN

Trial Description: The overall objective of this study is to assess the safety and efficacy of the LUM Imaging System in imaging primary and metastatic cancer in the brain. This includes selecting a dose to determine the initial efficacy of LUM015 for the molecular imaging of low-grade gliomas, glioblastomas and cancer masses that have metastasized to the brain.

  • Conditions: glioblastoma, low grade glioma of brain, metastasis to brain
  • Phase: Feasibility / Pilot
  • Trial ID: NCT03717142
  • Protocol ID: 18-463

Enrolling

Stereotactic radiation in patients with small cell lung cancer and 1-6 brain metastases: A single arm, phase II trial

Trial Description: This research study is studying stereotactic radiation (focused/pinpoint radiation that targets each individual tumor but not the surrounding brain) instead of whole-brain radiation (radiation targeting the entire brain) as a possible treatment for patients with small cell lung cancer and 1-10 brain metastases. The intervention involved in this study is: -Stereotactic (focused, pinpoint) radiation

  • Conditions: brain metastases, small cell lung cancer
  • Phase: II
  • Trial ID: NCT03391362
  • Protocol ID: 17-550

Not Enrolling

A Phase II Trial of HKI-272 (Neratinib), Neratinib) and Capecitabine, and Neratinib and Ado-Trastuzumab Emtansine (T-DM1) for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases

Trial Description: The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain. Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2). In this research study, the investigators are looking to see how well neratinib works to decrease the size of or stabilize breast cancer that has spread to the brain. The investigators are also looking at how previous treatments have affected your thinking (or cognition) and how much neratinib reaches the central nervous system.

  • Conditions: breast cancer
  • Phase: II
  • Trial ID: NCT01494662
  • Protocol ID: 11-344

Not Enrolling

A PHASE 3 OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY OF NKTR-102 VERSUS TREATMENT OF PHYSICIAN’S CHOICE (TPC) IN PATIENTS WITH METASTATIC BREAST CANCER WHO HAVE STABLE BRAIN METASTASES AND HAVE BEEN PREVIOUSLY TREATED WITH AN ANTHRACYCLINE, A TAXANE, AND CAPECITABINE

Trial Description: This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine in either the adjuvant or metastatic setting (prior anthracycline may be omitted if medically appropriate or contraindicated for the patient).

  • Conditions: breast cancer, metastasis
  • Phase: III
  • Trial ID: NCT02915744
  • Protocol ID: 16-553

Enrolling

S1827: MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

Trial Description: This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.

  • Conditions: extensive stage lung small cell carcinoma, limited stage lung small cell carcinoma, lung small cell carcinoma
  • Phase: III
  • Trial ID: NCT04155034
  • Protocol ID: 20-484

Not Enrolling

An open label phase Ib dose finding study of BI 836880 in combination with BI 754091 to characterize safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer and in other solid tumors

Trial Description: This study has 2 parts. The first part was open to adults with advanced non-small cell lung cancer. The second part was open also to adults with other types of advanced cancer of the lung, brain, skin, and liver. After early encouraging results, more people with liver cancer can now take part in the study. The participants get a combination of two medicines called BI 836880 and ezabenlimab. BI 836880 is a type of an antibody that blocks new blood vessel formation. New blood vessels are needed by the tumour to continue growing. Ezabenlimab is an antibody that may help

  • Conditions: neoplasms, non-squamous non-small-cell lung cancer
  • Phase: I
  • Trial ID: NCT03468426
  • Protocol ID: 19-823

Not Enrolling

A Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors

Trial Description: NUV-422-02 is a first-in-human, open-label, Phase 1/2 dose escalation and multiple expansion cohort study designed to evaluate the safety and efficacy of NUV-422. The study population is comprised of adults with recurrent or refractory high-grade gliomas (HGGs), metastatic breast cancer (mBC), with and without brain metastases, and recurrent or refractory metastatic castration-resistant prostate cancer (mCRPC). All patients will self-administer NUV-422 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.

  • Conditions: advanced breast cancer, advanced breast carcinoma, breast cancer, breast carcinoma, breast tumor, cancer of breast, cancer of prostate, cancer of the breast, cancer of the prostate, castrate resistant prostate cancer, castration resistant prostatic neoplasms, castration-resistant prostate cancer, glial cell tumors, glioblastoma, glioma, glioma malignant, glioma mixed, malignant tumor of breast, metastatic breast cancer, metastatic breast carcinoma, prostate cancer, prostate neoplasm, prostatic cancer, recurrent glioblastoma
  • Phase: I/II
  • Trial ID: NCT04541225
  • Protocol ID: 20-517

Enrolling

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

Trial Description: This research study is studying a novel drug called ALRN-6924 as a possible treatment for resistant (refractory) solid tumor, brain tumor, lymphoma or leukemia. The drugs involved in this study are: - ALRN-6924 - Cytarabine (for patients with leukemia only)

  • Conditions: brain tumor, leukemia, lymphoma, solid tumor
  • Phase: I
  • Trial ID: NCT03654716
  • Protocol ID: 18-284

Not Enrolling

A Phase 1/1b Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

in selected patient populations. Patients anticipated to be enrolled in Phase 1b will be selected based upon having a tumor type, including but not limited to, non small cell lung cancer and head and neck cancer positive for specific activating MET, NTRK2, NTRK3, or DDR2 mutations, MET or KIT/PDGFRA/KDR gene amplification, selected gene rearrangements involving the MET, RET, AXL, NTRK1, or NTRK3 gene loci, or having loss of function mutations in the CBL gene. In addition patients with clear cell renal cell carcinoma refractory to angiogenesis inhibitors or metastatic prostate cancer with bone metastasis will be enrolled.

  • Conditions: advanced cancer
  • Phase: I
  • Trial ID: NCT02219711
  • Protocol ID: 14-308

Enrolling

Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer

Trial Description: The overall goal of this study is to evaluate the effect of a testosterone drug called Depo-Testosterone (or 'testosterone cypionate'), an FDA-approved drug for improving fatigue, sexual function, quality of life, body composition, muscle strength, and physical activity in young cancer survivors who report fatigue and have low testosterone. Main hypothesis is that Testosterone administration in young male cancer survivors who are in remission for at least 1 year, report cancer-related fatigue and have symptomatic testosterone deficiency will be associated with greater improvements in fatigue scores compared with placebo.

  • Conditions: fatigue syndrome chronic, hypogonadism male
  • Phase: II
  • Trial ID: NCT04049331
  • Protocol ID: 19-646

Enrolling

An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY - Breast12)

Trial Description: This is open-label, multicenter, international study, assessing the efficacy and safety of Trastuzumab deruxtecan (T-DXd) in participants with or without brain metastasis (BMs), with previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed on prior anti-HER2-based regimens and who received no more than 2 lines/regimens of therapy in the metastatic setting (excluding tucatinib).

  • Conditions: breast cancer
  • Phase:
  • Trial ID: NCT04739761
  • Protocol ID: 22-067

Enrolling

Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-MET EXON 14 Skip Mutations and c-MET Dysregulation Advanced Solid Tumors

Trial Description: The primary Phase 1 purpose of this study was to assess overall safety, tolerability and recommended Phase 2 dose (RP2D) of APL-101. The Phase 2 portion will assess efficacy of the dose determined in Phase 1 in individuals with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations; individuals with cancers associated with c-Met amplifications; individuals with cancers associated with c-Met fusion

  • Conditions: advanced cancer, brain tumor, gastric cancer, gastroesophageal junction adenocarcinoma, glioblastoma multiforme, lung cancer, nsclc, renal cancer, solid tumor
  • Phase: I/II
  • Trial ID: NCT03175224
  • Protocol ID: 20-084

Not Enrolling

Phase 1 Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 (CC-90010) in Pediatric Cancer

Trial Description: Arm 1 of this research study is studying an investigational drug called BMS-986158 as a possible treatment for pediatric solid tumors or lymphoma. Arm 2 of this research study is studying an investigational drug called BMS-986378 (also known as CC-90010) as a possible treatment for pediatric brain tumors or pediatric tumors that have spread to the brain.

  • Conditions: brain tumor pediatric, lymphoma, solid tumor childhood
  • Phase: I
  • Trial ID: NCT03936465
  • Protocol ID: 19-040

Enrolling

Phase I trial of ASTX727 in recurrent/progressive non-enhancing IDH mutant gliomas

Trial Description: this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients

  • Conditions: neurological cancer
  • Phase: I
  • Trial ID: NCT03922555
  • Protocol ID: 18-631

Enrolling

RELAY: Repeated Magnetic Resonance Imaging Examinations to Analyze and Assess Your Cancer: A Prospective Study on the Use of Serial Magnetic Resonance Imaging in the Assessment of Changes during Treatment with Radiation Therapy

Trial Description: This is a phase 1 study to determine the feasibility and utility of using serial magnetic resonance imaging (MRI) to assess treatment response during and after radiation therapy (standard of care cancer treatment) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma. The research study procedures include three MRI scans (one pre treatment, during and post standard care cancer radiation therapy) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma. The research study procedures include: - Screening for eligibility - Three MRI scans

  • Conditions: esophageal cancer, glioblastoma, magnetic resonance imaging, mri, pediatric glioblastoma multiforme, prostate cancer, radiotherapy, vulvar cancer
  • Phase: I
  • Trial ID: NCT04188535
  • Protocol ID: 19-573

Enrolling

ACCL2031, A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors

Trial Description: This phase III trial compares memantine to usual treatment in treating patients with brain tumors that are newly diagnosed or has come back (recurrent). Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary brain tumor.

  • Conditions: brain neoplasm, recurrent brain neoplasm
  • Phase: III
  • Trial ID: NCT04939597
  • Protocol ID: 22-143

Enrolling

A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)

Trial Description: This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. - The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. - Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures

  • Conditions: adrenal metastases, borderline resectable pancreatic carcinoma, brain metastases, liver metastases, lung cancer, mesothelioma, metachronous nodal metastases, oligoprogressive nodal metastases, pancreas cancer, prostate cancer, renal cancer, spine metastases, synchronous nodal metastases
  • Phase: I/II
  • Trial ID: NCT04115254
  • Protocol ID: 19-353

Enrolling

A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors

Trial Description: This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor

  • Conditions: infantile fibrosarcoma, infantile myofibromatosis, medullary thyroid cancer, papillary thyroid cancer, soft tissue sarcoma
  • Phase: I/II
  • Trial ID: NCT03899792
  • Protocol ID: 19-026

Not Enrolling

An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with REGN2810 in Subjects with Newly-Diagnosed Glioblastoma (GBM)

Trial Description: Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM

  • Conditions: glioblastoma
  • Phase: I/II
  • Trial ID: NCT03491683
  • Protocol ID: 18-377

Not Enrolling

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Trial Description: This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion

  • Conditions: adult solid tumor, breast cancer, cholangiocarcinoma, colorectal cancer, head and neck neoplasms, lymphoma large-cell anaplastic, melanoma, neuroendocrine tumors, non-small cell lung cancer, ovarian cancer, pancreatic cancer, papillary thyroid cancer, primary brain tumors, renal cell carcinoma, salivary gland cancers, sarcomas
  • Phase: II
  • Trial ID: NCT02568267
  • Protocol ID: 15-435

Not Enrolling

Phase I Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

Trial Description: This research study seeks to gain new knowledge about the addition of a carefully targeted "boost" dose of radiation as a possible treatment for recurrent or metastatic head or neck cancer. The name of the study intervention involved in this study is stereotactic body radiotherapy, which is a way of delivering radiation in a more precisely targeted way and with a higher dose than conventional radiotherapy.

  • Conditions: head and neck cancer metastatic, head or neck cancer, recurrent head and neck carcinoma
  • Phase: I
  • Trial ID: NCT02474368
  • Protocol ID: 15-183

Enrolling

A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors

Trial Description: A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Anti-PD-1 in Patients with Metastatic Solid Tumors

  • Conditions: cholangiocarcinoma, colorectal cancer, metastatic cancer, pancreatic cancer, solid tumor
  • Phase: I/II
  • Trial ID: NCT04666688
  • Protocol ID: 20-668

Enrolling

A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First- Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)

Trial Description: A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  • Conditions: gastric adenocarcinoma, gastric cancer, gastroesophageal cancer
  • Phase: II
  • Trial ID: NCT04363801
  • Protocol ID: 20-433

Enrolling

OPTimizing Treatment Focused Genetic Testing IN Advanced Cancer- OPT-IN

Trial Description: This two-part randomized controlled trial aims to evaluate the impact of pre-test video education as compared to pre-test Chatbot education

  • Conditions: breast cancer, ovarian cancer, pancreatic cancer, prostate cancer
  • Phase: Not Applicable
  • Trial ID: NCT04066361
  • Protocol ID: 19-068

Enrolling

SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice

Trial Description: Deficits in the management of common symptoms cause substantial morbidity for cancer patients.Because the health care delivery system is structured to be reactive and not proactive, there are missed opportunities to optimize symptom control. Growth in Internet access and proliferation of smartphones has created an opportunity to re-engineer cancer care delivery. Electronic symptom tracking and feedback is a promising strategy to improve symptom control. Electronic patient reported outcome (ePRO) monitoring of cancer symptoms has been shown to decrease symptom burden, improve quality of life, reduce acute care and even extend survival. SIMPRO will use functioning ePRO prototypes to create and refine the electronic symptom management system eSyM

  • Conditions: gastrointestinal cancer, gynecologic cancer, other cancer, thoracic cancer
  • Phase: Not Applicable
  • Trial ID: NCT03850912
  • Protocol ID: 18-734

Not Enrolling

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-Expressing Tumors (DESTINY-PanTumor02)

Trial Description: This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study will enroll 7 tumor-specific cohorts: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and rare tumors. Study hypothesis: Trastuzumab deruxtecan will show meaningful clinical activity and a favorable risk benefit profile in selected HER2-expressing solid tumors.

  • Conditions: bladder cancer biliary tract cancer cervical cancer endometrial cancer ovarian cancer pancreatic cancer rare tumors
  • Phase: II
  • Trial ID: NCT04482309
  • Protocol ID: 21-051

Enrolling

A Randomized Controlled Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated with Cranial Radiation for Brain Tumors

Trial Description: Background: - More children with cancer are surviving into adulthood. Some side effects from treatment go away quickly. But some problems may not go away or may only show up months or years later. These problems are called late effects. Late effects can cause difficulties in cognitive functions, such as attention and memory. Physical activity has been found to improve the attention and memory skills of children with Attention Deficit Hyperactivity Disorder (ADHD). Researchers want to see if physical activity can help with these cognitive problems in children with brain

  • Conditions: brain tumor
  • Phase: Not Applicable
  • Trial ID: NCT02153957
  • Protocol ID: 18-585

Enrolling

Treatment response assessment maps (TRAMs) in the delineation of radiation necrosis from tumor progression after stereotactic radiation in patients with brain metastases: A prospective study

Trial Description: This research study is investigating the value of an imaging study of the brain called an MRI (which stands for magnetic resonance imaging), utilized in unique way, to delineate whether the tumor has recurred or whether radiation changes have occurred after a brain metastasis treated with focused radiation has enlarged.

  • Conditions: brain tumor
  • Phase: II
  • Trial ID: NCT04033497
  • Protocol ID: 19-191

Not Enrolling

Phase II Trial of Pembrolizumab in Central Nervous System Metastases from Multiple Histologies

Trial Description: This research study is studying Pembrolizumab as a possible treatment for this diagnosis for metastases in the central nervous system (brain and spinal cord).

  • Conditions: brain metastases
  • Phase: II
  • Trial ID: NCT02886585
  • Protocol ID: 16-153

Not Enrolling

A Phase II study of Lorlatinib (PF-06463922) in advanced ALK and ROS1 rearranged NSCLC with CNS metastasis in the absence of measurable extracranial lesions

Trial Description: This research study is studying a drug as a possible treatment for ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC). The following drug will be involved in this study : - Lorlatinib

  • Conditions: non-small cell lung cancer (nsclc)
  • Phase: II
  • Trial ID: NCT02927340
  • Protocol ID: 16-248

Enrolling

A Phase 1 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer

Trial Description: This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of BDTX-1535 in patients with GBM or NSCLC harboring sensitive EGFR alterations and who have disease progression following standard of care

  • Conditions: glioblastoma, non-small cell lung cancer
  • Phase: I
  • Trial ID: NCT05256290
  • Protocol ID: 22-295

Not Enrolling

Routine Evaluation of the Social Determinants of Health in Oncology: User-centered Resource Coordination and Engagement (RESOURCE)

Trial Description: The purpose of this research is to understand how screening for patient resource needs followed by customized resource matching can improve outcomes for adults with breast, lung or gastrointestinal cancer.

  • Conditions: breast cancer, gastrointestinal cancer, lung cancer
  • Phase: Feasibility / Pilot
  • Trial ID: NCT04879927
  • Protocol ID: 20-437

Enrolling

Comprehensive Outcomes for After Cancer Health (COACH): The Feasibility and Impact of an mHealth Augmented Coaching Program for Self-Management in Cancer Survivors

Trial Description: This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 500 individuals with diverse cancer diagnoses will be enrolled across up to 5 clinical sites to participate in a randomized wait-list control study. Those in the intervention group will receive 6 months of digital coaching up front followed by 6 months of ongoing monitoring via patient reported and clinical outcomes, as well as wearable data. Those in the control group

  • Conditions: breast cancer, gastric cancer, lung cancer, ovarian cancer, survivorship
  • Phase: Feasibility / Pilot
  • Trial ID: NCT05349227
  • Protocol ID: 21-737

Enrolling

Clinical Onboard Utilization of Image Guided Radiation Therapy with Magnetic Resonance (CONFIRM): A Master Protocol

Trial Description: This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved in this study is the MRIdian Linear Accelerator.

  • Conditions: bladder cancer, gastric cancer, in situ breast cancer, invasive breast cancer, larynx cancer, mantle cell lymphoma
  • Phase: I/II
  • Trial ID: NCT04368702
  • Protocol ID: 19-665

Enrolling

An Open-label, Dose Escalation and Expansion, Phase 1a/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advan

Trial Description: This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors. The aims of the study are: - to assess the safety profile of TAK-500 when given alone and when given with pembrolizumab. - to assess the effects of TAK-500, when given alone and when given with pembrolizumab, on adults with locally advanced or metastatic solid tumors. Participants may receive TAK-500 for up to 1 year. Participants may continue with their treatment if they have continuing benefit and if this is approved by their study

  • Conditions: breast cancer, esophageal cancer, gastric cancer, hepatocellular cancer, mesothelioma, non-small cell lung cancer (nsclc), pancreatic cancer, squamous cell cancer (scc)
  • Phase: I
  • Trial ID: NCT05070247
  • Protocol ID: 22-038

Not Enrolling

A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT, IN COMBINATION WITH CPI-444, AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS

Trial Description: This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers. CPI-006 will be evaluated as a single agent, in combination with ciforadenant (an oral adenosine 2A receptor antagonist), in combination with pembrolizumab (an anti-PD1 antibody), and in combination with ciforadenant and pembrolizumab.

  • Conditions: bladder cancer, cervical cancer, colorectal cancer, endometrial cancer, metastatic castration resistant prostate cancer, non-hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, renal cell cancer, sarcoma, squamous cell carcinoma of the head and neck, triple negative breast cancer
  • Phase: I
  • Trial ID: NCT03454451
  • Protocol ID: 18-335

Not Enrolling

Phase 1 Trial of Marizomib Alone and in Combination with Panobinostat for Children with Diffuse Intrinsic Pontine Glioma

Trial Description: This research study is evaluating the safety, tolerability and preliminary efficacy of the drugs marizomib and panobinostat in pediatric patients with diffuse intrinsic pontine glioma (DIPG). The names of the study drugs involved in this study are: - Marizomib - Panobinostat

  • Conditions: diffuse glioma, diffuse intrinsic pontine glioma, pediatric brain tumor, pediatric brainstem glioma, pediatric brainstem gliosarcoma recurrent, pediatric cancer
  • Phase: I
  • Trial ID: NCT04341311
  • Protocol ID: 19-654

Not Enrolling

Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (formerly known as CB- 1158) as a Single Agent and in Combination with Immune Checkpoint Therapy in Patients with Advanced/Metastatic Solid Tumors

Trial Description: This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors

  • Conditions: bladder cancer, colorectal cancer (crc), gastric cancer, head and neck cancer, lung cancer, mesothelioma, metastatic cancer, renal cell carcinoma (rcc), solid tumors, uc (urothelial cancer)
  • Phase: I
  • Trial ID: NCT02903914
  • Protocol ID: 17-427